Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Down 23.0% in January

Delcath Systems, Inc. (NASDAQ:DCTH) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 31st total of 1,350,000 shares. Based on an average daily trading volume, of 386,900 shares, the days-to-cover ratio is presently 2.7 days.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of DCTH. Principal Financial Group Inc. bought a new position in shares of Delcath Systems in the third quarter valued at $808,000. Renaissance Technologies LLC acquired a new position in Delcath Systems during the 2nd quarter valued at about $694,000. Jane Street Group LLC bought a new stake in Delcath Systems during the 3rd quarter worth approximately $110,000. Geode Capital Management LLC raised its stake in shares of Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock worth $2,275,000 after purchasing an additional 7,298 shares during the last quarter. Finally, Barclays PLC bought a new position in shares of Delcath Systems in the third quarter valued at approximately $104,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Down 2.1 %

NASDAQ DCTH opened at $15.65 on Thursday. Delcath Systems has a 52 week low of $3.70 and a 52 week high of $16.44. The business has a 50 day moving average price of $12.30 and a 200-day moving average price of $10.31. The company has a market cap of $500.33 million, a price-to-earnings ratio of -11.59 and a beta of 0.87.

Wall Street Analyst Weigh In

A number of brokerages have commented on DCTH. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Delcath Systems in a research note on Tuesday, January 14th. Stephens reissued a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. Craig Hallum raised their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.25.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.